1. Home
  2. VRDN

as 10-13-2025 3:54pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Medical Specialities

Nasdaq

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Founded: 2006 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 1.6B IPO Year: N/A
Target Price: $36.33 AVG Volume (30 days): 708.8K
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.56 EPS Growth: N/A
52 Week Low/High: $9.90 - $27.20 Next Earning Date: 11-11-2025
Revenue: $305,000 Revenue Growth: 5.90%
Revenue Growth (this year): -49.68% Revenue Growth (next year): 34044.63%

VRDN Daily Stock ML Predictions

Share on Social Networks: